Evidence map›Paper›PMID 35474460›Full record

ArticleJournal of medical virology2022

Evaluation of a new "all in one" SARS-CoV-2 antigen-detecting rapid diagnostic test and self-test: Diagnostic performance and usability in child and adult populations.

Thierry Prazuck, Anne Gravier, Daniela Pires-Roteira, Aurelie Theillay, Sandra Pallay, Mathilda Colin, Raphael Serreau, Laurent Hocqueloux, Nino Guy Cassuto

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Thierry PrazuckCentre gratuit d'information, de dépistage et de diagnostic (CeGIDD) Orléans, Centre Hospitalier Régional d'Orléans, Orléans, France.ORCID 0000-0002-2212-6873
Anne GravierCentre gratuit d'information, de dépistage et de diagnostic (CeGIDD) Orléans, Centre Hospitalier Régional d'Orléans, Orléans, France.
Daniela Pires-RoteiraCentre hospitalier régional d'Orléans, service des maladies infectieuses et tropicales, Orléans, France.
Aurelie TheillayCentre hospitalier régional d'Orléans, service des maladies infectieuses et tropicales, Orléans, France.
Sandra PallayCentre hospitalier régional d'Orléans, service des maladies infectieuses et tropicales, Orléans, France.
Mathilda ColinCentre hospitalier régional d'Orléans, service des maladies infectieuses et tropicales, Orléans, France.
Raphael SerreauService de médecine préventive, Orléans, France.
Laurent HocquelouxCentre hospitalier régional d'Orléans, service des maladies infectieuses et tropicales, Orléans, France.
Nino Guy CassutoLaboratoires Drouot, Paris, France.
Centre hospitalier universitaire d'Orléans · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The control of the COVID-19 epidemics has been one global health priorities for the last 2 years. To that end, more reliable and easy-to-use, regardless of age, diagnostic tests are necessary. Considering that, we evaluated an innovative two-step self-test, the AAZ COVID-VIRO ALL IN®, switching from the classic nasal swab to a nasal sponge. We performed a multicenter study, on 124 adults and children, in a point-of-care setting. Sensitivity, specificity and overall acceptance of the COVID-VIRO ALL IN® self-test compared to reverse transcriptase polymerase chain reaction (RT-PCR) on nasopharyngeal samples were of 93.0%, 100%, and 97.5%, respectively. We then performed a multicenter, usability study to evaluate the ease of use of COVID-VIRO ALL IN® on 68 laypersons adults. A vast majority of participants correctly executed and interpreted the test. The usability was then specifically investigated on 40 children and teenagers, comparing COVID-VIRO® first generation to the new COVID-VIRO ALL IN®. They all found COVID-VIRO ALL IN® more comfortable and easier to use. For young children, the new self-test seems safer (less risk of trauma and no liquid exposure), and faster than saliva-based RT-PCR. Moreover, the COVID-VIRO ALL IN® can easily be adapted as a multiplex self-test for other respiratory viruses, opening new perspectives of simultaneous, rapid and massive detection of respiratory infections, especially among vulnerable populations like children and elderly people.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultAgedChildChild, PreschoolDiagnostic Tests, RoutineHumansNasopharynxSelf-TestingSensitivity and Specificityantigen testingchildren COVID testingCOVID-19diagnostic testingnasal samplingSARS-CoV-2self-testusability

Identifiers

PMID35474460
PMCPMC9088384
OpenAlexW4224952728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.